Blockade of TNFα signaling can render lung cancer PDXs that express wild-type EGFR sensitive to the treatment of EGFR inhibitors, and improve the therapeutic effect of EGFR inhibitors in lung cancer PDXs with EGFR mutations32. The gene discussed is EGFR; the disease is lung cancer.